Skip to main content
. 2017 Nov 3;26:100–111. doi: 10.1016/j.ebiom.2017.10.030

Fig. 1.

Fig. 1

High expression of Aurora B predicts poor overall survival in ESCC patients. (a) Aurora B is highly expressed in human esophageal squamous carcinoma cells. Western blot analysis was performed to examine Aurora B expression in several ESCC cell lines and normal Het-1A cells. (b) Overall survival rates of ESCC patients with high (n = 45) or low (n = 35) expression levels of Aurora B were estimated with the Kaplan-Meier method by log-rank test (p < 0.0001). (c, d) Knocking down Aurora B expression in KYSE150 cells (c) and Eca109 cells (d) reduces their tumorigenic properties. MTS assay (left) and soft agar assay (middle and right) were performed as described in “Materials and Methods” (***p < 0.001 vs. sh-GFP group). (e) Knockdown of Aurora B reduces in vivo tumor growth of KYSE150 (left) and Eca109 (right) cells. Tumor growth curve of mice injected with KYSE150 and Eca109 was shown. Data are represented as means ± S.D. of each group (*p < 0.05 vs. vehicle-treated group).